AKNE-MYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Akne-mycin, and when can generic versions of Akne-mycin launch?
Akne-mycin is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in AKNE-MYCIN is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Akne-mycin
A generic version of AKNE-MYCIN was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for AKNE-MYCIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 4,239 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AKNE-MYCIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for AKNE-MYCIN
US Patents and Regulatory Information for AKNE-MYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | AKNE-MYCIN | erythromycin | OINTMENT;TOPICAL | 050584-001 | Jan 10, 1985 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |